Clinical significance of Src expression and activity in human neoplasia

Histology and Histopathology

Volumn 27, Issue 6, 2012, Pages 677-692

  Chatzizacharias, Nikolaos A ^a,b   Kouraklis, Gregory P ^a   Giaginis, Constantinos T ^a   Theocharis, Stamatios E ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Activity; Cancer; Expression; Malignancy; Src

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; PATHOLOGY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

ANIMALIA; RICE STRIPE VIRUS; ROUS SARCOMA VIRUS;

EID: 84859361361     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Akhand A.A., Pu M., Senga T., Kato M., Suzuki H., Miyata T., Hamaguchi M. and Nakashima I. (1999). Nitric oxide controls src kinase activity through a sulfhydryl group modification-mediated Tyr- 527-independent and Tyr-416-linked mechanism. J. Biol. Chem. 274, 25821-25826.
2. Aleshin A. and Finn R.S. (2010). SRC: a century of science brought to the clinic. Neoplasia 12, 599-607.
3. Aligayer H., Boyd D.D., Heiss M.M., Abdalla E.K., Curley S.A. and Gallick G.E. (2002). Activation of Src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis. Cancer 94, 344-351.
4. Anders C.K., Acharya C.R., Hsu D.S., Broadwater G., Garman K., Foekens J.A., Zhang Y., Wang Y., Marcom K., Marks J.R., Mukherjee S., Nevins J.R., Blackwell K.L. and Potti A. (2008). Agespecific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One 3, e1373.
5. Barnekow A., Paul E. and Schartl M. (1987). Expression of the c-src protooncogene in human skin tumors. Cancer Res. 47, 235-240.
6. Belshes-Jablonski A.P., Biscardi J.S., Peavy D.R., Tice D.A., Romney D.A. and Parsons S.J. (2001). Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 20, 1465-1475.
7. Benistant C., Chapuis H., Mottet N., Noletti J., Crapez E., Bali J.P. and Roche S. (2000). Deregulation of the cytoplasmic tyrosine kinase cSrc in the absence of a truncating mutation at codon 531 in human bladder carcinoma. Biochem. Biophys. Res. Commun. 273, 425-430.
8. Ben-Izhak O., Cohen-Kaplan V. and Nagler R.M. (2010). The prognostic role of phospho-Src family kinase analysis in tongue cancer. J. Cancer Res. Clin. Oncol. 136, 27-34.
9. Bjelfman C., Hedborg F., Johansson I., Nordenskjöld M. and Påhlman S. (1990). Expression of the neuronal form of pp60c-src in neuroblastoma in relation to clinical stage and prognosis. Cancer Res. 50, 6908-6914.
10. Bjorge J.D., Pang A. and Fujita D.J. (2000). Identification of proteintyrosine phsphatase 1b as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. J. Biol. Chem. 275, 41439-41446.
11. Bowman T., Broome M.A., Sinibaldi D., Wharton W., Pledger W.J., Sedivy J.M., Irby R., Yeatman T., Courtneidge S.A. and Jove R. (2001). Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc. Natl. Acad. Sci. USA 98, 7319-7324.
12. Brown M.T. and Copper J.A. (1996). Regulation, substrates and functions of src. Biochem. Biophys. Acta 1287, 121-149.
13. Campbell E.J., McDuff E., Tatarov O., Tovey S., Brunton V., Cooke T.G. and Edwards J. (2008). Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer. Br. J. Cancer 99, 1769-1774.
14. Cartwright C.A., Kamps M.P., Meisler A.I., Pipas J.M. and Eckhart W. (1989). Pp60c-src activation in human colon carcinoma. J. Clin. Invest. 83, 2025-2033.
15. Cartwright C.A., Meisler A.I. and Eckhart W. (1990). Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc. Natl. Acad. Sci. USA 87, 558-562.
16. Cartwright C.A., Coad C.A. and Egbert B.M. (1994). Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J. Clin. Invest. 93, 509-515.
17. Chatzizacharias N.A., Kouraklis G.P. and Theocharis S.E. (2008). Clinical significance of FAK in human neoplasia. Histol. Histopathol. 23, 629-650.
18. Chatzizacharias N.A., Giaginis C., Zizi-Serbetzoglou D., Kouraklis G.P., Karatzas G. and Theocharis S.E. (2010). Evaluation of the clinical significance of focal adhesion kinase and SRC expression in human pancreatic ductal adenocarcinoma. Pancreas 39, 930-936.
19. Chatzizacharias N.A., Giaginis C., Gatzidou E., Tsourouflis G., Sfiniadakis I., Alexandrou P. and Theocharis S.E. (2011). Expression and clinical significance of FAK and Src proteins in human endometrial adenocarcinoma. Pathol. Oncol. Res. 17, 277-285.
20. Chen T., Pengetnze Y. and Taylor C.C. (2005). Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9- independent activation of caspase-3. Mol. Cancer Ther. 4, 217-224.
21. Clinical Trials [database online]. Bethesda MD: National Cancer Institue. Available at: http://www.cancer.gov/clinicaltrials. Accessed April 9, 2011.
22. Clinical Trials [database online]. National Institute of Health. Available at: www.clinicaltrials.gov. Accessed April 9, 2011.
23. Collett M.S. and Erikson R.L. (1978) Protein kinase activity associated with the avian sarcoma virus src gene product. Proc. Natl. Acad. Sci. USA. 75, 2021-2024.
24. Contessa J.N., Abell A., Mikkelsen R.B., Valerie K. and Schmidt-Ullrich R.K. (2006). Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation. Breast Cancer Res. Treat. 95, 17-27.
25. Cooper J.A., Gould K.L., Cartwright C.A. and Hunter T. (1986). Tyr527 is phosphorylated in pp60c-src: implications for regulation. Science 231, 1431-1434.
26. Cote G.J. and Chiu J.F. (1987). The expressions of oncogenes and liver-specific genes in Morris hepatomas. Biochem. Biophys. Res. Commun. 143, 624-629.
27. Courtneidge S.A., Fumagalli S., Koegl M., Superti-Furga G. and Twamley-Stein G.M. (1993). The Src family of protein tyrosine kinases: regulation and functions. Development (Suppl). 57-64.
28. De Heer P., Joudijs M.M., van de Velde C.J.H., Aalbers R.I.J.M., Tollenaar R.A.E.M., Putter H., Morreau J., van de Water B. and Kuppen P.J.K. (2008). Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation. EJSO 34, 1253-1261.
29. DeMali K.A., Godwin S.L., Soltoff S.P. and Kazlauskas A. (1999). Multiple roles for Src in a PDGF-stimulated cell. Exp. Cell Res. 253, 271-279.
30. Desouki M.M. and Rowan B.G. (2004). SRC kinase and mitogenactivated protein kinases in the progression from normal to malignant endometrium. Clin. Cancer Res. 10, 546-555.
31. Detta A., Kenny B.G., Smith C., Logan A. and Hitchcock E. (1993). Correlation of proto-oncogene expression and proliferation and meningiomas. Neurosurgery 33, 1065-1074.
32. Di Florio A., Capurso G., Milione M., Panzuto F., Geremia R., Delle Fave G. and Sette C. (2007). Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells. Endocr. Relat. Cancer 14, 111-124.
33. Elsberger B., Tan B.A., Mitchell T.J., Brown S.B.F., Mallon E.A., Tovey S.M., Cooke T.G., Brunton V.G. and Edwards J. (2009). Is expression or activation of Src kinase associated with cancerspecific survival in ER-, PR- and HER2-negative breast cancer patients? Am. J. Pathol. 175, 1389-1397.
34. Elsberger B., Fullerton R., Zino S., Jordan F., Mitchell T.J., Brunton V.G., Mallon E.A., Shiels P.G. and Edwards J. (2010). Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. Br. J. Cancer 103, 899-909.
35. Fanning P., Bulovas K., Saini K.S., Libertino J.A., Joyce A.D. and Summerhayes I.C. (1992). Elevated expression of pp60c-src in low grade human bladder carcinoma. Cancer Res. 52, 1457-1462.
36. Frame M.C. (2002). Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 1602, 114-130.
37. Frame M.C. (2004). Newest findings on the oldest oncogene; how activated src does it. J. Cell Sci. 117, 989-998.
38. George J.A., Chen T. and Taylor C.C. (2005). SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res. 65, 10381-10388.
39. Guarino M. (2010). Src signaling in cancer invasion. J. Cell Physiol. 223, 14-26.
40. Hakam A., Fang Q., Karl R. and Coppola D. (2003). Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig. Dis. Sci. 48, 1972-1978.
41. Han N.M., Curley S.A. and Gallick G.E. (1996). Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin. Cancer Res. 2, 1397-1404.
42. Hennipman A., van Oirschot J., Smits J., Rijksen G. and Staal G.E.J. (1989). Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue. Cancer Res. 49, 516-521.
43. Hingorani P., Zhang W., Gorlick R. and Kolb E.A. (2009). Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin. Cancer Res. 15, 3416-3422.
44. Hiscox S., Morgan L., Green T.P., Barrow D., Gee J. and Nicholson R.I. (2006). Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res. Treat. 97, 263-274.
45. Hiscox S., Jordan N.J., Morgan L., Green T.P. and Nicholson R.I. (2007). Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin. Exp. Metastasis 24, 157-167.
46. Homsi J., Cubitt C.L., Zhang S., Munster P.N., Yu H., Sullivan D.M., Jove R., Messina J.L. and Daud A.I. (2009). Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 19, 167-175.
47. Horn S., Meyer J., Stocking C., Ostertag W. and Jucker M. (2003). An increase in the expression and total activity of endogenous p60(c- Src) in several factor-independent mutants of a human GM-CSFdependent leukemia cell line (TF-1). Oncogene 22, 7170-7180.
48. Hunter T. and Sefton B.M. (1980). Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA 77, 1311-1315.
49. Iravani S., Mao W., Fu L., Karl R., Yeatman T., Jove R. and Coppola D. (1998). Elevated c-Src protein expression is an early event in colonic neoplasia. Lab. Invest. 78, 365-371.
50. Iravani S., Zhang H.Q., Yuan Z.Q., Cheng J.Q., Karl R.C., Jove R. and Coppola D. (2003). Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia. Hum. Pathol. 34, 975-982.
51. Irby R.B., Mao W., Coppola D., Kang J., Loubeau J.M., Trudeau W., Karl R., Fujita D.J., Jove R. and Yeatman T.J. (1999). Activating SRC mutation in a subset of advanced human colon cancers. Nature Genet. 21, 187-190.
52. Irino S., Tanaka T. and Kubota Y. (1988). Alteration of p60c-src expression in human leukemia-lymphoma cells correlated with induced differentiation. Jpn. J. Med. 27, 135-141.
53. Ito Y., Kawakatsu H., Takeda T., Sakon M., Nagano H., Sakai T., Miyoshi E., Noda K., Tsujimoto M., Wakasa K., Monden M. and Matsuura N. (2001). Activation of c-Src gene product in hepatocellular carcinoma is highly correlated with the indices of early stage phenotype. J. Hepatol. 35, 68-73.
54. Ito Y., Kawakatsu H., Takeda T., Tani N., Kawaguchi N., Noguchi S., Sakai T. and Matsuura N. (2002). Activation of c-Src is inversely correlated with biological aggressiveness of breast carcinoma. Breast Cancer Res. Treat. 76, 261-267.
55. Jacobs C. and Rubsamen H. (1983). Expression of pp60c-src protein kinase in adult and fetal human tissue: High activities in some sarcomas and mammary carcinomas. Cancer Res. 43, 1696-1702.
56. Jankowski J., Coghill G., Hopwood D. and Wormsley K.G. (1992). Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 33, 1033-1038.
57. Jove R. and Hanafusa H. (1987). Cell transformation by the viral src oncogene. Annu. Rev. Cell Biol. 3, 31-56.
58. Jung E.J. and Kim C.W. (2002). Interaction between chicken protein tyrosine phosphatase 1 (CPTP-1)-like rat protein phosphatase (PTP1) and pp60(v-src) in v-src-transformed Rat-1 fibroblasts. Exp. Mol. Med. 34, 476-480.
59. Ke J., Chelvarajan R.L., Sindhava V., Robertson D.A., Lekakis L., Jennings C.D. and Bondada S. (2009). Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. Mol. Cancer 8, 132-146.
60. Kitanaka A., Waki M., Kamano H., Tanaka T., Kubota Y., Ohnishi H., Takahara J. and Irino S. (1994). Antisense src expression inhibits proliferation and erythropoietin-induced erythroid differentiation of K562 human leukemia cells. Biochem. Biophys. Res. Commun. 201, 1534-1540.
61. Kong L., Deng Z., Zhao Y., Wang Y., Sarkar F.H. and Zhang Y. (2011). Down-regulation of phospho-non-receptor Src tyrosine kinases contributes to growth inhibition of cervical cancer cells. Med. Oncol. 28, 1495-1506.
62. Kopetz S., Shah A.N. and Gallick G.E. (2007). Src continues aging: current and future clinical directions. Clin. Cancer Res 13, 7232-7236.
63. Koster A., Landgraf S., Leipold A., Sachse R., Gebhart E., Tulusan A.H., Ronay G., Schmidt C. and Dingermann T. (1991). Expression of oncogenes in human breast cancer specimens. Anticancer Res. 11, 193-201.
64. Krueger J.G., Garber E.A., Goldberg A.R. and Hanafusa H. (1982). Changes in amino-terminal sequences of pp60src lead to decreased membrane association and decreased in vivo tumorigenicity. Cell 28, 889-896.
65. Kumble S., Omary M.B., Cartwright C.A. and Triadafilopoulos G. (1997). Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology 112, 348-356.
66. Landgren E., Blume-Jensen P., Courtneidge S.A. and Claesson-Welsh L. (1995). Fibroblast growth factor receptor-1 regulation of the Src family kinases. Oncogene 10, 2027-2035.
67. Lau G.M., Lau G.M., Yu G.L., Gelman I.H., Gutowski A., Hangauer D. and Fang J.W. (2009). Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig. Dis. Sci. 54, 1465-1474.
68. LaVallee T.M., Prudovsky I.A., McMahon G.A., Hu X. and Maciag T. (1998) Activation of the MAP kinase pathway by FGF-1 correlates with cell proliferation induction while activation of the Src pathway correlates with migration. J. Cell Biol. 141, 1647-58.
69. Lee J.H., Pyon J.K., Kim D.W., Lee S.H., Nam H.S., Kim C.H., Kang S.G., Lee Y.J., Park M.Y., Jeong D.J. and Cho M.K. (2010). Elevated c-Src and c-Yes expression in malignant skin cancers. J. Exp. Clin. Cancer Res. 29, 116.
70. Leung E.L.H., Tam I.Y.S., Tin V.P.C., Chua D.T.T., Sihoe A.D.L., Cheng L.C., Ho J.C.M., Chung L.P. and Wong M.P. (2009). Src promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for moleculrtarget therapy. Mol. Can. Res. 7, 923-932.
71. Levinson A.D., Oppermann H., Levintow L., Varmus H.E. and Bishop J.M. (1978). Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein. Cell 15, 561-572.
72. Licato L.L. and Brenner D.A. (1998). Analysis of signaling protein kinases in human colon or colorectal carcinomas. Dig. Dis. Sci. 43, 1454-1464.
73. Loganzo F. Jr, Dosik J.S., Zhao Y., Vidal M.J., Nanus D.M., Sudol M. and Albino A.P. (1993). Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. Oncogene 8, 2637-2644.
74. Luttrell D.K., Lee A., Lansing T.J., Crosby R.M., Jung K.D., Willard D., Luther M., Rodriguez M., Berman J. and Gilmer T.M. (1994). Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc. Natl. Acad. Sci. USA 91, 83-7.
75. Madan R., Smolkin M.B., Cocker R., Fayyad R. and Oktay M.H. (2006). Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma. Hum. Pathol. 37, 9-15.
76. Mao W., Irby R., Coppola D., Fu L., Wloch M., Turner J., Yu H., Garcia R., Jove R. and Yeatman T.J. (1997). Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15, 3083-3090.
77. Martin G.S. (1970). Rous sarcoma virus: a function required for the maintenance of the transformed state. Nature. 227, 1021-1023.
78. Masaki T., Okada M., Shiratori Y., Rengifo W., Matsumoto K., Maeda S., Kato N., Kanai F., Komatsu Y., Nishioka M. and Omata M. (1998). pp60c-src activation in hepatocellular carcinoma of humans and LEC rats. Hepatology 27, 1257-1264.
79. Masaki T., Okada M., Tokuda M., Shiratori Y., Hatase O., Shirai M., Nishioka M. and Omata M. (1999). Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma. Hepatology. 29, 379-384.
80. Masaki T., Igarashi K., Tokuda M., Yukimasa S., Han F., Jin Y.J., Li J.Q., Yoneyama H., Uchida N., Fujita J., Yoshiji H., Watanabe S., Kurokohchi K. and Kuriyama S. (2003). Pp60c-src activation in lung adenocarcinoma. Eur. J. Cancer 39, 1447-1455.
81. Matsunaga T., Takahashi H., Ohnuma N., Tanabe M., Yoshida H., Iwai J., Shirasawa H. and Simizu B. (1991). Expression of N-myc and csrc protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas. Cancer Res. 51, 3148-3152.
82. Matsunaga T., Shirasawa H., Enomoto H., Yoshida H., Iwai J., Tanabe M., Kawamura K., Etoh T. and Ohnuma N. (1998). Neuronal src and trk a protooncogene expression in neuroblastomas and patient prognosis. Int. J. Cancer 79, 226-231.
83. Mavilio F., Sposi N.M., Petrini M., Bottero L., Marinucci M., De Rossi G., Amadori S., Mandelli F. and Peschle C. (1986). Expression of cellular oncogenes in primary cells from human acute leukemias. Proc. Natl. Acad. Sci. USA 83, 4394-4398.
84. Mayer B.J., Jackson P.K. and Baltimore D. (1991). The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosinephosphorylated cellular proteins with high affinity. Proc. Natl. Acad. Sci. USA 88, 627-631.
85. Mazurenko N.N., Kogan E.A., Zborovskaya I.B. and Kisseljov F.L. (1992). Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur. J. Cancer 28, 372-377.
86. Michailidi C., Giaginis C., Stolakis V., Alexandrou P., Klijanienko J., Delladetsima I., Chatzizacharias N., Tsourouflis G. and Theocharis S. (2010). Evaluation of FAK and Src Expression in Human Benign and Malignant Thyroid Lesions. Pathol. Oncol. Res. 16, 497-507.
87. Morgan L., Gee J., Pumford S., Farrow L., Finlay P., Robertson J., Ellis I., Kawakatsu H., Nicholson R. and Hiscox S. (2009). Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol. Ther. 8, 1550- 1558.
88. Mori S., Rönnstrand L., Yokote K., Engström A., Courtneidge S.A., Claesson-Welsh L. and Heldin C.H. (1993). Identification of two juxtamembrane autophosphorylation sites in the PDGFß-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J. 12, 2257-2264.
89. Morton J.P., Karim S.A., Graham K., Timpson P., Jamieson N., Athineos D., Doyle B., McKay C., Heung M.Y., Oien K.A., Frame M.C., Evans T.R., Sansom O.J. and Brunton V.G. (2010). Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 139, 292-303.
90. Mostertz W., Stevenson M., Acharya C., Chan I., Walters K., Lamlertthon W., Barry W., Crawford J., Nevins J. and Potti A. (2010). Age- and sex-specific genomic profiles in non-small cell lung cancer. JAMA 303, 535-543.
91. Muthuswamy S.K., Siegel P.M., Dankort D.L., Webster M.A. and Muller W.J. (1994). Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol. Cell Biol. 14, 735-743.
92. Nagaraj N.S., Smith J.J., Revetta F., Washington M.K. and Merchant N.B. (2010). Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol. Cancer Ther. 9, 2322-2332.
93. Nakagawa T., Tanaka S., Suzuki H., Takayanagi H., Miyazaki T., Nakamura K. and Tsuruo T. (2000). Overexpression of the csk gene suppresses tumor metastasis in vivo. Int. J. Cancer 88, 384-391.
94. Nanus D.M., Lynch S.A., Rao P.H., Anderson S.M., Jhanwar S.C. and Albino A.P. (1991). Transformation of human kidney proximal tubule cells by a src-containing retrovirus. Oncogene 6, 2105-2111.
95. Ottenhoff-Kalff A.E., Rijksen G., van Beurden E.A., Hennipman A., Michels A.A. and Staal G.E. (1992). Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product. Cancer Res. 52, 4773-4778.
96. Paronetto M.P., Farini D., Sammarco I., Maturo G., Vespasiani G., Geremia R., Rossi P. and Sette C. (2004). Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. Am. J. Pathol. 164, 1243-1251.
97. Parsons J.T and Weber M.J. (1989). Genetics of src: structure and functional organization of a protein tyrosine kinase. Curr. Top Microbiol. Immunol. 147, 79-127.
98. Planas-Silva M.D. and Hamilton K.N. (2007). Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins. Cancer Chemother. Pharmacol. Cancer Chemother. Pharmacol. 60, 535-543.
99. Punt C.J.A., Rijksen G., Van Oirschot B.A., Kester-Schipper G.P.M., Van der Heijden M.C.M., Dekker A.W. and Staal G.E.J. (1992). Partial characterization of protein tyrosine kinases in human lymphoid cells. Anticancer Res. 12, 2075-2084.
100. Rahimi N., Hung W., Tremblay E., Saulnier R. and Elliott B. (1998). c- Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J. Biol. Chem. 273, 33714-33721.
101. Reissig D., Clement J., Sanger J., Berndt A., Kosmehl H. and Bohmer F.D. (2001). Elevated activity and expression of Srcfamily kinases in human breast carcinoma tissue versus matched non-tumor tissue. J. Cancer Res. Clin. Oncol. 127, 226-230.
102. Ren R., Mayer B.J., Cicchetti P. and Baltimore D. (1993). Identification of a ten-amino acid proline-rich SH3 binding site. Science 259, 1157-1161.
103. Riggins R.B., Thomas K.S, Ta H.Q., Wen J., Davis R.J., Schuh N.R., Donelan S.S., Owen K.A., Gibson M.A., Shupnik M.A., Silva C.M., Parsons S.J., Clarke R. and Bouton A.H. (2006). Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res. 66, 7007-7015.
104. Rous P.A. (1911a). A sarcoma of the fowl transmissible by an agent separable from the tumor cells. J. Exp. Med. 13, 397-411.
105. Rous P.A. (1911b). Transmission of a malignant new growth by means of a cell-free filtrate. JAMA 56, 198.
106. Sakai T., Kawakatsu H., Fujita M., Yano J. and Owada M.K. (1998). An epitope localized in c-Src negative regulatory domain is a potential marker in early stage of colonic neoplasms. Lab. Invest. 78, 219-225.
107. Schaller M.D., Hildebrand J.D., Shannon J.D., Fox J.W., Vines R.R. and Parsons J.T. (1994). Autophosphorylaiton of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of the pp60src. Mol. Cell Biol. 14, 1680-1688.
108. Sefton B.M., Trowbridge I.S., Cooper J.A. and Scolnick E.M. (1982). The transforming proteins of Rous sarcoma virus and Abelson virus contain tightly bound lipid. Cell 31, 465-474.
109. Songyang Z., Shoelson S.E., Chaudhuri M., Gish G., Pawson T., Haser W.G., King F., Roberts T., Ratnofsky S., Lechleider R.J., Neel B.G., Raymond B., Birge R.B., Fajardo J.E., Chou M.M., Hanafusa H., Schaffhausen B. and Cantley L.C. (1993). SH2 domains recognize specific phosphopeptide sequences. Cell 72, 767-778
110. Stover D.R., Furet P. and Lydon N.B. (1996). Modulation of the SH2 binding specificity and kinase activity of Src by tyrosine phosphorylation within its SH2 domain. J. Biol. Chem. 271,12481-12487.
111. Sugimura M., Kobayashi K., Sagae S., Nishioka Y., Ishioka S., Terasawa K., Tokino T. and Kudo R. (2000). Mutation of the SRC gene in endometrial carcinoma. Jpn. J. Cancer Res. 91, 396-398.
112. Summy J.M. and Gallick G.E. (2003). Src family kinases in tumor progression and metastasis. Cancer Met. Rev. 22, 337-358.
113. Takekura N., Yasui W., Yoshida K., Tsujino T., Nakayama H., Kameda T., Yokozaki H., Nishimura Y., Ito H. and Tahara E. (1990). pp60csrc protein kinase activity in human gastric carcinomas. Int. J. Cancer 45, 847-851.
114. Takenaka N., Mikoshiba K., Takamatsu K., Tsukada Y., Ohtani M. and Toya S. (1985). Immunohistochemical detection of the gene product of Rous sarcoma virus in human brain tumors. Brain Res. 337, 201-207.
115. Takeya T. and Hanafusa H. (1982). DNA sequence of the viral and cellular src gene of chickens. II. Comparison of the src genes of two strains of avian sarcoma virus and of the cellular homolog. J. Virol. 44, 12-18.
116. Talamonti M.S., Roh M.S., Curley S.A. and Gallick G.E. (1993). Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J. Clin. Invest. 91, 53-60.
117. Tatarov O., Mitchell T.J., Seywright M., Leung H.Y., Brunton V.G. and Edwards J. (2009). SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res. 15, 3540-3549.
118. Termuhlen P.M., Curley S.A., Talamonti M.S., Saboorian M.H. and Gallick G.E. (1993). Site-specific differences in pp60c-src activity in human colorectal metastases. J. Surg. Res. 54, 293-298.
119. Thomas J.W., Ellis B., Boerner R.J., Knight W.B., White G.C. 2nd and Schaller M.D. (1998). NSH2- and SH3-mediated interactions between focal adhesion kinase and Src. J. Biol. Chem. 273, 577-583.
120. Tice D.A., Biscardi J.S., Nickles A.L. and Parsons S.J. (1999). Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 96, 1415-1420.
121. Timpson P., Jones G.E., Frame M.C. and Brunton V.G. (2001). Coordination of cell polarization and migration by the Rho family GTPases requires Src tyrosine kinase activity. Curr. Biol. 11, 1836-1846.
122. Tsao A.S., He D., Saigal B., Liu S., Lee J.J., Bakkannagari S., Ordonez N.G., Hong W.K., Wistuba I. and Johnson F.M. (2007). Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol. Can. Ther. 6, 1962-1972.
123. van Oijen M.G., Rijksen G., ten Broek F.W. and Slootweg P.J. (1998). Overexpression of c-Src in areas of hyperproliferation in head and neck cancer, premalignant lesions and benign mucosal disorders. J. Oral Pathol. Med. 27, 147-152.
124. Verbeek B.S., Vroom T.M., Adriaansen-Slot S.S., Ottenhoff-Kalff A.E., Geertzema J.G., Hennipman A. and Rijksen G. (1996). C-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J. Pathol. 180, 383-388.
125. Vigneron A., Roninson I.B., Gamelin E. and Coqueret O. (2005). Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res. 65, 8927-8935.
126. Waki M., Kitanaka A., Kamano H., Tanaka T., Kubota Y., Ohnishi H., Takahara J. and Irino S. (1994). Antisense src expression inhibits U937 human leukemia cell proliferation in conjunction with reduction of c-myb expression. Biochem. Biophys. Res. Commun. 201, 1001-1007.
127. Waksman G., Shoelson S.E., Pant N., Cowburn D. and Kuriyan J. (1993). Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell 72, 779-790.
128. Weber T.K., Steele G. and Summerhayes I.C. (1992). Differential pp60c-src activity in well and poorly differentiated human colon carcinomas and cell lines. J. Clin. Invest. 90, 815-821.
129. Wiener J.R., Windham T.C., Estrella V.C., Parikh N.U., Thall P.F., Deavers M.T., Bast R.C., Mills G.B. and Gallick G.E. (2003). Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Genecol. Oncol. 88, 73-79.
130. Wilson G.R., Cramer A., Welman A., Knox F., Swindell R., Kawakatsu H., Clarke R.B., Dive C. and Bundred N.J. (2006). Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br. J. Cancer 95, 1410-1414.
131. Xu W., Harrison S.C. and Eck M.J. (1997). Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602.
132. Yamaguchi H. and Hendrickson W.A. (1996). Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 231, 484-489.
133. Yeatman T.J. (2004). A renaissance for Src. Nat. Rev. Cancer 4, 470-480.
134. Yeo M.G., Partridge M.A., Ezratty E.J., Shen Q., Gundersen G.G. and Marcantonio E.E. (2006). Src SH2 arginine 175 is required for cell motility: specific focal adhesion kinase targeting and focal adhesion assembly function. Mol. Cell Biol. 26, 4399-4409.
135. Zhang X.H., Wang Q., Gerald W., Hudis C.A., Norton L., Smid M., Foekens J.A. and Massagué J. (2009). Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16, 67-78.
136. Zhang X.K., Huang D.P., Chiu D.K. and Chiu J.F. (1987). The expression of oncogenes in human developing liver and hepatomas. Biochem. Biophys. Res. Commun. 142, 932-938.
137. Zheng X.M., Wang Y. and Pallen C.J. (1992). Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase. Nature 359, 336-339.
138. Zou D., Yoon H.S., Anjomshoaa A., Perez D., Fukuzawa R., Guilford P. and Humar B. (2009). Increased levels of active c-Src distinguish invasive from in situ lobular lesions. Breast Cancer Res. 11, R45.
139. Zou J.X., Liu Y., Pasquale E.B. and Ruoslahti E. (2002). Activated SRC oncogene phosphorylates R-ras and suppresses integrin activity. J. Biol. Chem. 277, 1824-1827.